Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
RegulatorypositiveZeydovioPositive
AI Analysis
Summary
Zealand Pharma received a positive CHMP opinion for Zeydovio (glepaglutide) for treating short bowel syndrome, a significant regulatory milestone toward European market approval.
Outcome Details
positive CHMP (Committee for Medicinal Products for Human Use) opinion
Importance:8/10
Sentiment:
0.85
regulatory approvalCHMP opinionEuropeglepaglutideshort bowel syndrome
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 18, 2026 10:10 AM